Moderna's stock took a significant hit following a downgrade from Citigroup, raising concerns over its valuation amid ambitious sales expectations.
Shares of Moderna Inc. (NASDAQ:MRNA) fell sharply yesterday, closing down 5.35% at CA$192.57. The decline was primarily driven by a Sell downgrade from Citigroup, which warned that the company's current valuation is unsustainable given its ambitious revenue projections.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$76.88B
52W high
$208.90
52W low
$22.28
1W change
+5.74%
Beta
1.11
Analyst Price Targets
Based on 27 analysts covering MRNA · as of Sep 17, 2026
Wall Street analysts forecast MRNA stock price to fall 37.9% over the next 12 months.
Consensus
Hold3.22 / 5.00
Avg. Target
C$119.56
-37.9% Upside
Current Price
C$192.57
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
316.4%
Annualized
90-Day Vol
212.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$230.22
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$204.38 | C$68.61 – C$608.81 |
| 60 trading days | C$216.92 | C$46.33 – C$1015.51 |
| 90 trading days | C$230.22 | C$34.76 – C$1524.77 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Moderna's recent stock surge may not be justified by its underlying fundamentals, particularly in the oncology space.
5.35% decline in Moderna's stock yesterday
The stock's drop reflects investor skepticism about its lofty valuation amidst a challenging market environment.
Bull case
Moderna's innovative pipeline, including its cancer vaccine, could lead to significant revenue in the future if successful. This potential may justify its current valuation.
Bear case
The recent downgrade raises concerns about whether Moderna's valuation is sustainable, especially given the aggressive sales forecasts and challenges in the oncology market.
Advertisement
The Downgrade Impact
Citigroup's downgrade from Neutral to Sell sent shockwaves through Moderna's stock. Analysts noted that the recent surge in share price was driven by unrealistic sales expectations. They indicated that reaching a near-$200 share price would require nearly $13 billion in annual oncology revenue, a target they deemed overly ambitious.
Market Reaction and Future Outlook
The market reacted quickly to the downgrade, with Moderna's shares reflecting skepticism about its valuation. Investors now face the challenge of weighing the potential of Moderna's innovative pipeline against the backdrop of increased scrutiny and tough market conditions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
